Hoeflich A, Nedbal S, Blum W F, Erhard M, Lahm H, Brem G, Kolb H J, Wanke R, Wolf E
Institutes of Molecular Animal Breeding, Animal Physiology, and Veterinary Pathology, Ludwig-Maximilian University, 81377 Munich, Germany.
Endocrinology. 2001 May;142(5):1889-98. doi: 10.1210/endo.142.5.8149.
To clarify the role of insulin-like growth factor (IGF)-binding protein-2 (IGFBP-2) in postnatal growth regulation, we crossed hemizygous CMV-IGFBP-2 transgenic mice with hemizygous PEPCK-bGH transgenic mice, which are characterized by serum GH levels in the range of 2 microgram/ml. Four genetic groups were obtained: animals carrying both transgenes (GB), the GH (G) or the IGFBP-2 transgene (B), and nontransgenic controls (C). Male offspring were analyzed for serum levels of IGF-I, for serum and tissue levels of IGFBP-2, and for body and organ growth. Serum IGF-I levels were 2- to 3-fold increased (P < 0.001) in the GH-overexpressing groups, with no difference between G and GB mice. Serum IGFBP-2 levels were 4- to 9-fold (P < 0.001) increased both in B and GB vs. C and G mice. Western immunoblot analysis did not reveal differences in tissue IGFBP-2 levels between B and GB mice. IGFBP-2 levels were highest in pancreas, followed by skeletal muscle, heart, kidney, brain, skin, and spleen. No elevation of IGFBP-2 was found in the liver. Body weight gain of G and GB mice was significantly increased vs. C and B mice, resulting in almost 2-fold increased body weights at the age of 15 weeks. However, there was a significant reduction in body weight of GB vs. G mice (17%; P < 0.001) and of B vs. C mice (13%; P < 0.05). This was primarily caused by a marked reduction of carcass weight (GB vs. G, 27%; B vs. C, 21%; P < 0.001). Measurements of nose-rump-length, organ (brain, heart, spleen, liver, pancreas, kidney), and tissue weights (skin, carcass, abdominal fat) in 5- and 15-week-old mice revealed several indications that the growth-inhibiting effect of IGFBP-2 overexpression was more marked in high-GH/IGF-I mice: 1) At 5 weeks of age, GB mice displayed a significant reduction of all growth parameters except for the weight of abdominal fat, when compared with G mice, whereas only brain weight was significantly reduced in B vs. C mice. 2) In 15-week-old animals, a significant reduction in all growth parameters, except for spleen and abdominal fat weights, was seen in GB vs. G mice, whereas only nose-rump-length and the weights of carcass and brain were significantly reduced in B vs. C mice. Our study demonstrates, for the first time, the potential of IGFBP-2 to inhibit GH-stimulated growth in giant transgenic mice, providing further evidence for an inhibitory effect of this IGFBP in vivo.
为阐明胰岛素样生长因子(IGF)结合蛋白-2(IGFBP-2)在出生后生长调节中的作用,我们将半合子CMV-IGFBP-2转基因小鼠与半合子PEPCK-bGH转基因小鼠进行杂交,后者的特征是血清生长激素(GH)水平在2微克/毫升左右。获得了四个遗传组:携带两种转基因的动物(GB)、GH转基因动物(G)或IGFBP-2转基因动物(B)以及非转基因对照动物(C)。对雄性后代进行了IGF-I血清水平、IGFBP-2血清和组织水平以及身体和器官生长情况的分析。在GH过表达组中,血清IGF-I水平升高了2至3倍(P<0.001),G小鼠和GB小鼠之间无差异。与C小鼠和G小鼠相比,B小鼠和GB小鼠的血清IGFBP-2水平升高了4至9倍(P<0.001)。Western免疫印迹分析未显示B小鼠和GB小鼠在组织IGFBP-2水平上存在差异。IGFBP-2水平在胰腺中最高,其次是骨骼肌、心脏、肾脏、大脑、皮肤和脾脏。在肝脏中未发现IGFBP-2升高。与C小鼠和B小鼠相比,G小鼠和GB小鼠的体重增加显著,在15周龄时体重几乎增加了2倍。然而,GB小鼠与G小鼠相比体重显著降低(17%;P<0.001),B小鼠与C小鼠相比体重也显著降低(13%;P<0.05)。这主要是由于胴体重量显著降低所致(GB小鼠与G小鼠相比,降低27%;B小鼠与C小鼠相比,降低21%;P<0.001)。对5周龄和15周龄小鼠的鼻臀长度、器官(大脑、心脏、脾脏、肝脏、胰腺、肾脏)和组织重量(皮肤、胴体、腹部脂肪)进行测量,结果显示了几个迹象,表明IGFBP-2过表达的生长抑制作用在高GH/IGF-I小鼠中更为明显:1)在5周龄时,与G小鼠相比,GB小鼠除腹部脂肪重量外的所有生长参数均显著降低,而与C小鼠相比,B小鼠仅脑重量显著降低。2)在15周龄的动物中,与G小鼠相比,GB小鼠除脾脏和腹部脂肪重量外的所有生长参数均显著降低,而与C小鼠相比,B小鼠仅鼻臀长度以及胴体和脑重量显著降低。我们的研究首次证明了IGFBP-2在巨型转基因小鼠中具有抑制GH刺激生长的潜力,为该IGFBP在体内的抑制作用提供了进一步的证据。